Azerbaijan, Baku, Feb. 6 / Trend S.Isayev, T. Jafarov/
Iran has launched domestic manufacturing of Factor VII protein, which is used in treating hemophilia, IRNA reported.
Factor VII (formerly known as proconvertin) is one of the proteins that causes blood to clot in the coagulation cascade. It is an enzyme (EC 184.108.40.206) of the serine protease class.
Hemophilia is a group of inherited blood disorders in which the blood does not clot properly. Bleeding disorders are due to defects in the blood vessels, the coagulation mechanism, or the blood platelets. An affected individual may bleed spontaneously or for longer than a healthy person after injury or surgery.
At the hosted event timed to the Fajr celebrations, it was also noted that along with Factor VII, Iran also started production of recombinant monoclonal antibodies. Iran's president Mahmoud Ahmadinejad was present at the event.
The production of recombinant monoclonal antibodies involves technologies, referred to as repertoire cloning or phage display/yeast display. Recombinant antibody engineering involves the use of viruses or yeast to create antibodies.
These techniques rely on rapid cloning of immunoglobulin gene segments to create libraries of antibodies with slightly different amino acid sequences from which antibodies with desired specificities can be selected.
They can also be used to enhance the specificity with which antibodies recognize antigens, their stability in various environmental conditions, their therapeutic efficacy, and their detectability in diagnostic applications.
It was noted that both medications will be manufactured by Aryogen Research & Manufacturing complex in Iran.
According to IRINN TV channel, there are only two manufacturing complexes in the world that produce Factor VII, one of which is in Denmark. The other one is in Iran.
Domestic manufacturing and production of the above mentioned medications will allow Iran to save around $100 mln each year, since the country was importing the both medications from other countries.
Do you have any feedback? Contact our journalist at email@example.com
Follow us on Twitter @TRENDNewsAgency